Illumina (ILMN)

• Market cap: $12.3B
• 1 day: 2.09%
• 5 days: 9.37%
• 1 month: -11.57%
• 3 months: -42.86%
• 6 months: -44.95%
• Year to date: -40.55%
• 1 year: -36.65%
• 5 years: -74.81%
• 10 years: -58.94%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Employees: 8,970

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

73% more call options, than puts

Call options by funds: $344M | Put options by funds: $199M

71% more first-time investments, than exits

New positions opened: 145 | Existing positions closed: 85

12% more capital invested

Capital invested by funds: $18.3B [Q3] → $20.6B (+$2.27B) [Q4]

9.1% more ownership

Funds ownership: 88.24% [Q3] → 97.34% (+9.1%) [Q4]

7% more funds holding in top 10

Funds holding in top 10: 14 [Q3] → 15 (+1) [Q4]

6% more funds holding

Funds holding: 792 [Q3] → 837 (+45) [Q4]

15% less repeat investments, than reductions

Existing positions increased: 256 | Existing positions reduced: 300

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $77 1% downside
• Avg. target: $123 59% upside
• High target: $190 144% upside

9 analyst ratings

• positive: 4 44%
• neutral: 4 44%
• negative: 1 11%

Barclays Luke Sergott 24% 1-year accuracy 14 / 58 met price target	1% downside $77	Underweight Maintained	10 Apr 2025
RBC Capital Conor McNamara 13% 1-year accuracy 5 / 38 met price target	44% upside $112	Outperform Maintained	8 Apr 2025
Citigroup Patrick Donnelly 19% 1-year accuracy 6 / 31 met price target	9% upside $85	Neutral Maintained	7 Apr 2025
Stephens & Co. Mason Carrico 12% 1-year accuracy 3 / 26 met price target	100% upside $156	Overweight Reiterated	11 Mar 2025
Canaccord Genuity Kyle Mikson 34% 1-year accuracy 10 / 29 met price target	48% upside $115	Hold Maintained	11 Mar 2025